TLR9 and ovarian cancer: In an ovarian cancer model, the combination of TLR9 agonists (CpG oligodeoxynucleotides, CpG-ODNs) and anti-PD-1 antibodies can influence macrophage polarization by shifting them toward an immunoregulatory phenotype.